Syndax Pharmaceuticals Inc (SNDX NASDAQ) stock market data APIs
$9.5233
0.14(1.5%)
as of July 11, 2025
Try our APIs with
free plan!
Syndax Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Prev. Close
9.5233
Open
9.6653
High
9.8212
Low
9.4058
52 wk Range
8.58-25.07
Market Cap
898 M
Shares Outstanding
86 047 K
Revenue
43 722 K
EPS
-0.9846
Beta
0.745
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Syndax Pharmaceuticals Inc data using free add-ons & libraries
Get Syndax Pharmaceuticals Inc Fundamental Data
Syndax Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 43 722 K
- EBITDA: -343 660 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -1.2734
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Syndax Pharmaceuticals Inc News
New
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in bot...
Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock
Syndax Pharmaceuticals , Inc. (NASDAQ:SNDX), a biotechnology company with a market capitalization of $860 million focused on developing cancer treatments, has recently made significant strides in the ...
Kura Oncology's SWOT analysis: ziftomenib's potential reshapes AML treatment stock outlook
Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company with a market capitalization of $564 million, is making significant strides in the development of precision medicines for ...
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses ob...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
